Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 2Breast Neoplasms 2Lung Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Carcinoma, Small Cell 1

Interventions

Carboplatin 67Cisplatin 57Paclitaxel 42Radiotherapy 35Pemetrexed 34Gemcitabine 31Docetaxel 31Etoposide 25pembrolizumab 21Vinorelbine 20Erlotinib Hydrochloride 13Magnetic Resonance Spectroscopy 12Gefitinib 11Specimen Handling 10Radiosurgery 10Drug Therapy 10Bevacizumab 10durvalumab 9Nivolumab 9Vinblastine 6Topotecan 6Surgical Procedures, Operative 6Cyclophosphamide 6atezolizumab 5Standard of Care 5Platinum 5Immunoglobulin G 5Ifosfamide 5Disulfides 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lung Neoplasms × EC regimen × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡